Compare IDT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | ANAB |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 1996 | 2015 |
| Metric | IDT | ANAB |
|---|---|---|
| Price | $77.30 | $45.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $87.25 |
| AVG Volume (30 Days) | 128.6K | ★ 371.5K |
| Earning Date | 12-03-2026 | 11-12-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | 14.95 | ★ 91.02 |
| EPS | ★ 3.46 | 0.11 |
| Revenue | ★ $1,231,495,000.00 | $234,603,000.00 |
| Revenue This Year | $2.39 | $28.82 |
| Revenue Next Year | $0.75 | $24.35 |
| P/E Ratio | ★ $22.47 | $414.64 |
| Revenue Growth | 2.13 | ★ 157.01 |
| 52 Week Low | $46.48 | $33.10 |
| 52 Week High | $84.56 | $73.30 |
| Indicator | IDT | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 40.38 |
| Support Level | $51.16 | $44.25 |
| Resistance Level | $84.48 | $57.55 |
| Average True Range (ATR) | 2.14 | 1.70 |
| MACD | -0.86 | -0.11 |
| Stochastic Oscillator | 14.00 | 18.60 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).